Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 29, 2006
Business Overview: Greatbatch is a leading developer and manufacturer of components for implantable medical devices (IMDs) and commercial power sources. Operations are divided into two segments: Implantable Medical Components (IMC) and Electrochem Commercial Power (ECP). The company expanded into value-added assembly in 2005 with a new facility in Tijuana, Mexico.
Key Financial Metrics
| Metric | 2006 (in millions) | 2005 (in millions) |
|---|---|---|
| Total Sales | $271.1 | $241.1 |
| Net Income | $16.1 | $10.1 |
| Diluted EPS | $0.73 | $0.46 |
| Operating Cash Flow | $39.2 | $43.3 |
| Working Capital | $199.1 | $152.0 |
| Total Assets | $547.8 | $512.9 |
| Long-term Debt | $170.0 | $170.0 |
| Operating Margin | 8.3% | 7.0% |
| Net Margin | 5.9% | 4.2% |
Liquidity: The company held $142.6 million in cash, cash equivalents, and short-term investments as of December 29, 2006. It maintains a $50.0 million revolving credit facility with no outstanding balance at year-end.
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 12% to $271.1 million. The IMC segment grew 9% despite a decline in the underlying cardiac rhythm management market, driven by new assembly products and feedthroughs. The ECP segment surged 32% due to market penetration in oil and gas and telematics.
- Profitability: Net income rose 60% to $16.1 million, and operating income increased 33% to $22.4 million. This was achieved despite a 2% reduction in selling prices for IMC products.
- Cost Structure: Cost of sales as a percentage of sales improved to 62.2% (down from 64.4%) due to production efficiencies and the elimination of excess capacity costs at the capacitor facility. However, SG&A expenses increased 23% primarily due to the adoption of SFAS No. 123(R) requiring expensing of stock-based compensation ($3.2 million impact) and CEO transition costs.
- Restructuring: The company recorded $17.1 million in other operating expenses related to facility consolidations (Alden, Carson City, Columbia) and severance. This compares to $18.6 million in 2005.
Guidance, Outlook, and Risks
2007 Outlook: Management expects total sales to increase approximately 10%, targeting a range of $295 million to $305 million. This assumes a 5% underlying medical market growth rate. The company anticipates completing plant consolidation initiatives to achieve a cumulative annual savings run rate of $10 million. Capital spending is expected to range from $35.0 million to $45.0 million, with $28.0 million allocated to ECP facility expansion.
Management Commentary: The CEO highlighted successful execution of the strategic plan, including the launch of the "Q" battery series and the ramp-up of ECP manufacturing. The company is focused on penetrating the neurostimulation market and developing MRI-safe solutions.
Risks and Contingencies:
- Customer Concentration: Three customers (Boston Scientific, Medtronic, St. Jude Medical) accounted for 67% of total sales in 2006. Loss of any major customer would materially harm the business.
- Supply Chain: Reliance on a limited number of suppliers for critical raw materials (e.g., lithium, tantalum) creates vulnerability to price fluctuations and supply interruptions.
- Intangible Assets: Intangible assets represent 39% of total assets ($211.4 million). Impairment of goodwill or indefinite-lived intangibles could result in significant charges to earnings.
- Legal: Ongoing litigation includes a 2002 action by a former customer alleging misuse of proprietary information (potential loss $0.0 to $1.7 million) and actions by former employees regarding consolidation initiatives.
Investor Verification Checklist
- Verify the status of contract negotiations with top three customers (Boston Scientific, Medtronic, St. Jude Medical), as several agreements expired or are up for renewal in 2007.
- Monitor the completion of facility consolidations (Carson City and Columbia) and the realization of the projected $10 million annual savings.
- Assess the impact of raw material price volatility (specifically tantalum and lithium) on future margins.
- Review the progress of the ECP facility expansion project ($28 million) and its ability to capture growth in the oil and gas and telematics sectors.
- Confirm the adoption and financial impact of SFAS No. 123(R) on future stock-based compensation expenses.